Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTUD7B | Q6GQQ9 | 8/20 | 0.68 |
| ▸ | USP30 | Q70CQ3 | 10/20 | 0.63 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.53 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25052373 | 1.00 | OTUD7B (0.68) | OTUD7BUSP30UCHL1MKNK1 | |
| SCHEMBL17632028 | 0.94 | OTUD7B (0.61) | OTUD7BUSP30UCHL1MKNK1 | |
| SCHEMBL17632124 | 0.86 | OTUD7B (0.76) | OTUD7BUSP30UCHL1MKNK1 | |
| SCHEMBL25052368 | 0.86 | OTUD7B (0.76) | OTUD7BUSP30UCHL1MKNK1 | |
| SCHEMBL19281681 | 0.84 | OTUD7B (0.71) | OTUD7BUSP30UCHL1MKNK1 | |
| SCHEMBL17632460 | 0.83 | OTUD7B (0.49) | OTUD7BUSP30UCHL1 | |
| SCHEMBL17632480 | 0.82 | OTUD7B (0.47) | OTUD7BUSP30MKNK1 | |
| SCHEMBL19049845 | 0.81 | OTUD7B (1.00) | OTUD7BUSP30UCHL1 | |
| SCHEMBL19031337 | 0.81 | OTUD7B (1.00) | OTUD7BUSP30UCHL1 | |
| SCHEMBL17643981 | 0.81 | OTUD7B (0.75) | OTUD7BUSP30UCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3828179-A1 | CYANOPYRROLIDINES AS DUB MODULATORS | Mission Therapeutics Limited (GB) | 2021-06-02 | — | — | EP | claimed |
| EP-3197883-B1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2020-03-18 | — | — | EP | claimed |
| CN-107001339-B | Novel compounds | 特殊治疗有限公司 | 2020-03-17 | — | — | CN | claimed |
| US-10392380-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2019-08-27 | — | — | US | claimed |
| US-20180162852-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LIMITED | 2018-06-14 | — | — | US | claimed |
| US-9926307-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2018-03-27 | — | — | US | claimed |
| US-20170247365-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2017-08-31 | — | — | US | claimed |
| US-11993595-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2024-05-28 | — | — | US | disclosed |
| CN-111592534-B | New compounds | 特殊治疗有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20230052191-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2023-02-16 | — | — | US | disclosed |
| US-11472798-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2022-10-18 | — | — | US | disclosed |
| EP-3828179-A1 | CYANOPYRROLIDINES AS DUB MODULATORS | Mission Therapeutics Limited (GB) | 2021-06-02 | — | — | EP | disclosed |
| EP-3828179-A1 | CYANOPYRROLIDINES AS DUB MODULATORS | Mission Therapeutics Limited (GB) | 2021-06-02 | — | — | EP | disclosed |
| US-9926307-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2018-03-27 | — | — | US | disclosed |
| US-9926307-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2018-03-27 | — | — | US | disclosed |
| US-20170247365-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2017-08-31 | — | — | US | disclosed |
| US-20170247365-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2017-08-31 | — | — | US | disclosed |
| US-20170247365-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2017-08-31 | — | — | US | disclosed |
| EP-3197883-A1 | NOVEL COMPOUNDS | Mission Therapeutics Limited (GB) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016046530-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472798-B2 | Compounds | UCHL1, UCHL3, UCHL5 | OTUD7B 57/4885USP30 20/4885UCHL1 1/4885 |
| US-20180162852-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | OTUD7B 64/4885USP30 19/4885UCHL1 1/4885 |
| US-10392380-B2 | Compounds | UCHL1, UCHL3, UCHL5 | OTUD7B 57/4885USP30 20/4885UCHL1 1/4885 |
| US-11993595-B2 | Compounds | UCHL1, UCHL3, UCHL5 | OTUD7B 57/4885USP30 20/4885UCHL1 1/4885 |
| US-20170247365-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | OTUD7B 64/4885USP30 19/4885UCHL1 1/4885 |
| US-20230052191-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | OTUD7B 64/4885USP30 19/4885UCHL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.